Bayer AG has agreed to pay Algeta ASA up to $800 million for the experimental cancer treatment, Alpharadin [radium-223]. The drug is in Phase III clinical trials and may be beneficial for patients with cancer that has spread to the bones.
저작권자 © 메디칼업저버 무단전재 및 재배포 금지